Insmed Incorporated
INSM
株式のランク
#1114
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
株価
$93.98
最終同期: 2026-10-21
時価総額
$20.52B
変化（1日）
-1.77%
変化（1年）
-41.41%
国
US
取引 Insmed Incorporated (INSM)
カテゴリー
Healthcare
Insmed Incorporated（INSM）の株価履歴
終値の最高値: $100.34 （2026-10-01）
終値の最安値: $139.94 （2000-06-01）
終値の最安値: $139.94 （2000-06-01）
Insmed Incorporated の株価履歴（2000 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | -25.88% |
| 2025 | 163.90% |
| 2024 | 150.02% |
| 2023 | 48.62% |
| 2022 | -29.22% |
| 2021 | -27.29% |
| 2020 | 59.86% |
| 2019 | 62.30% |
| 2018 | -51.70% |
| 2017 | 128.88% |
| 2016 | -24.86% |
| 2015 | 16.87% |
| 2014 | -8.76% |
| 2013 | 145.55% |
| 2012 | 112.00% |
| 2011 | -49.13% |
| 2010 | -19.73% |
| 2009 | 46.16% |
| 2008 | -42.34% |
| 2007 | -13.04% |
| 2006 | -35.82% |
| 2005 | -15.49% |
| 2004 | -33.15% |
| 2003 | 447.28% |
| 2002 | -85.64% |
| 2001 | 16.21% |
| 2000 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.00 | 7.59% |
CH
|
